Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal C
A phase 3 trial of Bevacizumab in ovarian cancer, run by AbbVie, active and no longer recruiting.
Overview
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer is a phase 3 interventional study registered as NCT05445778 by AbbVie, with 520 participants enrolled, started 2023-03-15 and due to reach its primary completion in 2027-04. Interventions recorded: Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab. Conditions listed: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN1
Shares AbbVie (incl. ImmunoGen, Capstan), Bevacizumab, Ovarian cancer.
- TrialA Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Fo
Shares AbbVie (incl. ImmunoGen, Capstan), Bevacizumab, Ovarian cancer.
- TrialA Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult
Shares AbbVie (incl. ImmunoGen, Capstan), Bevacizumab, Ovarian cancer.
- TrialA Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer Wit
- TrialA Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primar
- TrialMirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ov
- TrialA Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Shares Bevacizumab, Ovarian cancer.
- TrialStudy of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-
Shares Bevacizumab, Ovarian cancer.